POSA56 A Cost-Effectiveness Analysis of Polatuzumab in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Portugal
- Resource Type
- Abstract
- Source
- In
Value in Health January 2022 25(1) Supplement:S43-S44 - Subject
- Language
- ISSN
- 1098-3015